Nussler Andreas, Konig Sarah, Ott Michael, Sokal Etienne, Christ Bruno, Thasler Wolfgang, Brulport Marc, Gabelein Geredn, Schormann Wiebke, Schulze Maren, Ellis Ewa, Kraemer Matthias, Nocken Frank, Fleig Wolfgang, Manns Michael, Strom Steven C, Hengstler Jan G
Fresenius Biotech Bad Homburg, Division of Cell Therapy, Bad Homburg, Germany.
J Hepatol. 2006 Jul;45(1):144-59. doi: 10.1016/j.jhep.2006.04.002. Epub 2006 Apr 27.
In recent years the interest in liver cell therapy has been increasing continuously, since the demand for whole liver transplantations in human beings far outweighs the supply. From the clinical point of view, transplantation of hepatocytes or hepatocyte-like cells may represent an alternative to orthotopic liver transplants in acute liver failure, for the correction of genetic disorders resulting in metabolically deficient states, and for late stage liver disease such as cirrhosis. Although the concept of cell therapy for various diseases of the liver is widely accepted, the practical approach in humans often remains difficult. An international expert panel critically discussed the recent published data on clinical and experimental hepatocyte transplantation and the possible role of stem cells in liver tissue repair. This paper aims to summarise the present status of cell based therapies for liver diseases and to identify areas of future preclinical and clinical research.
近年来,肝细胞治疗的关注度持续上升,因为人类对全肝移植的需求远远超过了供应。从临床角度来看,肝细胞或类肝细胞移植可能是急性肝衰竭原位肝移植的替代方案,可用于纠正导致代谢缺陷状态的遗传疾病,以及治疗肝硬化等晚期肝病。尽管针对各种肝病的细胞治疗概念已被广泛接受,但在人体中的实际应用往往仍存在困难。一个国际专家小组对最近发表的关于临床和实验性肝细胞移植的数据以及干细胞在肝组织修复中的可能作用进行了批判性讨论。本文旨在总结基于细胞的肝病治疗现状,并确定未来临床前和临床研究的领域。